POSB211 Is an Early Access Program for an Oncology Drug an Asset in the French Pricing and Reimbursement Pathway?
| Autor: | Cogez, F, Gervais, M, Cardon, SC, Kachaner, I, Bougeois, M |
|---|---|
| Zdroj: | In Value in Health January 2022 25(1) Supplement:S145-S145 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect